These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34479916)

  • 1. Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib.
    Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2021; 18(5):637-643. PubMed ID: 34479916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kawaguchi K; Kiyuna T; Miyake M; Igarashi K; Zhang Z; Murakami T; Li Y; Nelson SD; Elliott I; Russell T; Singh A; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(6):722-727. PubMed ID: 29334307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review.
    Higuchi T; Igarashi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Bouvet M; Tsuchiya H; Hoffman RM
    Anticancer Res; 2021 Dec; 41(12):5865-5871. PubMed ID: 34848441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium.
    Harrison DJ; Gill JD; Roth ME; Zhang W; Teicher B; Erickson S; Gatto G; Kurmasheva RT; Houghton PJ; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28222. PubMed ID: 32207565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Kiyuna T; Tome Y; Miyake K; Murakami T; Oshiro H; Igarashi K; Kawaguchi K; Hsu J; Singh M; Li Y; Nelson S; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4775-4779. PubMed ID: 31519578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Aug; 39(8):4079-4084. PubMed ID: 31366491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
    Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteosarcoma of the Breast in a Patient Derived Orthotopic Xenograft (PDOX) Mouse Model Is Arrested by both Cisplatinum and Eribulin.
    Masaki N; Wu NF; Aoki Y; Yamamoto J; Miyazaki J; Hoffman RM
    In Vivo; 2021; 35(6):3107-3110. PubMed ID: 34697141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
    Davis LE; Bolejack V; Ryan CW; Ganjoo KN; Loggers ET; Chawla S; Agulnik M; Livingston MB; Reed D; Keedy V; Rushing D; Okuno S; Reinke DK; Riedel RF; Attia S; Mascarenhas L; Maki RG
    J Clin Oncol; 2019 Jun; 37(16):1424-1431. PubMed ID: 31013172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
    Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model.
    Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Belt P; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4781-4786. PubMed ID: 31519579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma.
    Higuchi T; Oshiro H; Miyake K; Sugisawa N; Han Q; Tan Y; Park J; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Chawla SP; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4653-4657. PubMed ID: 31519563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.